Serum levels of interleukin 6, a potent myeloma cell growth factor, as a reflect of disease severity in plasma cell dyscrasias.
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Using a specific and very sensitive (1 pg = 1 U) bioassay, we investigated the presence of IL-6, a potent myeloma cell growth factor, in the sera of 131 subjects with plasma cell dyscrasias. 22 had monoclonal gammopathy of undetermined significance (MGUS), 13 had smoldering myeloma (SMM), 85 had overt multiple myeloma (MM), and 11 had plasma cell leukemia (PCL). Significant serum IL-6 levels were detected in only 3% of the MGUS/SMM group, but in 35% of the overt MM group and 100% of the PCL group. During overt MM, IL-6 was detected in 37% of the patients at diagnosis, 13% of those with stable MM, and 60% of those with fulminating disease. These data demonstrate that serum levels of IL-6, a potent myeloma cell growth factor in vitro, correlate with disease severity in plasma cell dyscrasias. Serial studies performed in 3 patients and correlative studies with labeling index in vivo in 25 patients have confirmed this concept. Taken together, this suggests that this cytokine is probably involved in vivo during the progressive phase of MM. Thus, anti-IL-6 or anti-IL-6 receptor antibodies could be useful as therapeutic agents at this stage of the disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Production of hybridoma growth factor by human monocytes
Aarden, L. A., De Groot, E. R., Schaap, O. L., & Lansdorp, P. M. (1987) · European Journal of Immunology · doi:10.1002/eji.1830171004 · Cited by 1,092
Houssiau, F. A., Devogelaer, J., Damme, J. V., Deuxchaisnes, C. N. D., & Snick, J. V. (1988) · Arthritis & Rheumatism · doi:10.1002/art.1780310614 · Cited by 847 · cited 3×
“In this last disease serum IL-6 levels are a reliable reflect of disease activity (10).”
BackgroundExcessive production of interleukin 6/B cell stimulatory factor-2 in rheumatoid arthritis
Hirano, T., Matsuda, T., Turner, M., Miyasaka, N., Buchan, G., Tang, B., Sato, K., Shimi, M., Maid, R., Feldmann, M., et al. (1988) · European Journal of Immunology · doi:10.1002/eji.1830181122 · Cited by 784
Klein, B., Zhang, X., Jourdan, M., Content, J., Houssiau, F., Aarden, L., Piechaczyk, M., & Bataille, R. (1989) · Blood · doi:10.1182/blood.v73.2.517.517 · Cited by 763
Self-citationVan Damme, J., Opdenakker, G., Simpson, R. J., Rubira, M. R., Cayphas, S., Vink, A., Billiau, A., & Van Snick, J. (1987) · The Journal of experimental medicine · doi:10.1084/jem.165.3.914 · Cited by 669
Multiple actions of interleukin 6 within a cytokine network
Wong, G. G., & Clark, S. C. (1988) · Immunology Today · doi:10.1016/0167-5699(88)91200-5 · Cited by 529
Functional discrimination between interleukin 6 and interleukin 1
Helle, M., And, L. B., & Aarden, L. A. (1988) · European Journal of Immunology · doi:10.1002/eji.1830181010 · Cited by 424
Interleukin 6 (IL-6) in serum and urine of renal transplant recipients.
van Oers, M. H. J., Heyden, A., & Aarden, L. A. (1988) · PubMed · Cited by 267
Interleukin-6 is a potent myeloma-cell growth factor in patients with aggressive multiple myeloma
Zhang, X., Klein, B., & Bataille, R. (1989) · Blood · doi:10.1182/blood.v74.1.11.11 · Cited by 266
Self-citationHoussiau, F. A., Bukasa, K. S., Sindic, C., Damme, J. V., & Snick, J. V. (1988) · PubMed · Cited by 226
Cited by
Interleukin-6 in Biology and Medicine
Akira, S., Taga, T., & Kishimoto, T. (1993) · Advances in Immunology · doi:10.1016/s0065-2776(08)60532-5 · Cited by 1,389
Age-Associated Increased Interleukin-6 Gene Expression, Late-Life Diseases, and Frailty
Ershler, W. B., & Keller, E. T. (2000) · Annual Review of Medicine · doi:10.1146/annurev.med.51.1.245 · Cited by 1,282
Biological and clinical aspects of interleukin 6
Hirano, T., Akira, S., Taga, T., & Kishimoto, T. (1990) · Immunology Today · doi:10.1016/0167-5699(90)90173-7 · Cited by 1,066
Cytokine Serum Level During Severe Sepsis in Human IL-6 as a Marker of Severity
DAMA, P., LEDOUX, D., NYS, M., VRINDTS, Y., GROOTE, D. D., FRANCHIMONT, P., & LAMY, M. (1992) · Annals of Surgery · doi:10.1097/00000658-199204000-00009 · Cited by 808
Multiple Myeloma: Increasing Evidence for a Multistep Transformation Process
Hallek, M., Leif Bergsagel, P., & Anderson, K. C. (1998) · Blood · doi:10.1182/blood.v91.1.3 · Cited by 752
Translating IL-6 biology into effective treatments
Choy, E. H., De Benedetti, F., Takeuchi, T., Hashizume, M., John, M. R., & Kishimoto, T. (2020) · Nature Reviews Rheumatology · doi:10.1038/s41584-020-0419-z · Cited by 668
Dankbar, B., Padró, T., Leo, R., Feldmann, B., Kropff, M., Mesters, R. M., Serve, H., Berdel, W. E., & Kienast, J. (2000) · Blood · doi:10.1182/blood.v95.8.2630 · Cited by 566
Chauhan, D., Uchiyama, H., Akbarali, Y., Urashima, M., Yamamoto, K., Libermann, T., & Anderson, K. (1996) · Blood · doi:10.1182/blood.v87.3.1104.bloodjournal8731104 · Cited by 563
Gupta, D., Treon, S., Shima, Y., Hideshima, T., Podar, K., Tai, Y., Lin, B., Lentzsch, S., Davies, F., Chauhan, D., et al. (2001) · Leukemia · doi:10.1038/sj.leu.2402295 · Cited by 553
Guise, T. A., & Mundy, G. R. (1998) · Endocrine Reviews · doi:10.1210/edrv.19.1.0323 · Cited by 472
Dendritic cells are functionally defective in multiple myeloma: the role of interleukin-6
Ratta, M., Fagnoni, F., Curti, A., Vescovini, R., Sansoni, P., Oliviero, B., Fogli, M., Ferri, E., Della Cuna, G. R., Tura, S., et al. (2002) · Blood · doi:10.1182/blood.v100.1.230 · Cited by 442
Map kinase signaling pathways and hematologic malignancies
Platanias, L. C. (2003) · Blood · doi:10.1182/blood-2002-12-3647 · Cited by 432
Murine anti-interleukin-6 monoclonal antibody therapy for a patient with plasma cell leukemia
Klein, B., Wijdenes, J., Zhang, X., Jourdan, M., Boiron, J., Brochier, J., Liautard, J., Merlin, M., Clement, C., & Morel-Fournier, B. (1991) · Blood · doi:10.1182/blood.v78.5.1198.1198 · Cited by 418
Self-citationRole of Monocytes in Atherogenesis
ØSTERUD, B., & BJØRKLID, E. (2003) · Physiological Reviews · doi:10.1152/physrev.00005.2003 · Cited by 412
Choi, S. J., Cruz, J. C., Craig, F., Chung, H., Devlin, R. D., Roodman, G. D., & Alsina, M. (2000) · Blood · doi:10.1182/blood.v96.2.671 · Cited by 408
Solitary plasmacytoma of bone and asymptomatic multiple myeloma
Dimopoulos, M. A., Moulopoulos, L. A., Maniatis, A., & Alexanian, R. (2000) · Blood · doi:10.1182/blood.v96.6.2037 · Cited by 397
Interleukin‐6: Structure‐function relationships
Simpson, R. J., Hammacher, A., Smith, D. K., Matthews, J. M., & Ward, L. D. (1997) · Protein Science · doi:10.1002/pro.5560060501 · Cited by 371
Tumor necrosis factor-?, interleukin-1?, and interleukin-6 expression in inflammatory bowel disease
Stevens, C., Walz, G., Singaram, C., Lipman, M. L., Zanker, B., Muggia, A., Antonioli, D., Peppercorn, M. A., & Strom, T. B. (1992) · Digestive Diseases and Sciences · doi:10.1007/bf01300378 · Cited by 331
Han, J.-H., Choi, S. J., Kurihara, N., Koide, M., Oba, Y., & Roodman, G. D. (2001) · Blood · doi:10.1182/blood.v97.11.3349 · Cited by 328
A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma
McCloskey, MacLennan, Drayson, Chapman, Dunn, Kanis, & Adults, F. T. M. W. P. O. L. I. (1998) · British Journal of Haematology · doi:10.1046/j.1365-2141.1998.00567.x · Cited by 314
Biology of Osteoclast Activation in Cancer
Roodman, G. D. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.15.3562 · Cited by 306
Hinson, R. M., Williams, J. A., & Shacter, E. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.10.4885 · Cited by 302
C-reactive protein and beta-2 microglobulin produce a simple and powerful myeloma staging system
Bataille, R., Boccadoro, M., Klein, B., Durie, B., & Pileri, A. (1992) · Blood · doi:10.1182/blood.v80.3.733.733 · Cited by 294
Self-citationControl of programmed cell death in normal and leukemic cells: new implications for therapy
Sachs, L., & Lotem, J. (1993) · Blood · doi:10.1182/blood.v82.1.15.bloodjournal82115 · Cited by 284
Zhang, X., Gaillard, J., Robillard, N., Lu, Z., Gu, Z., Jourdan, M., Boiron, J., Bataille, R., & Klein, B. (1994) · Blood · doi:10.1182/blood.v83.12.3654.3654 · Cited by 276
Self-citationChauhan, D., Kharbanda, S., Ogata, A., Urashima, M., Teoh, G., Robertson, M., Kufe, D. W., & Anderson, K. C. (1997) · Blood · doi:10.1182/blood.v89.1.227 · Cited by 272
Biologic effects of anti-interleukin-6 murine monoclonal antibody in advanced multiple myeloma
Bataille, R., Barlogie, B., Lu, Z., Rossi, J., Lavabre-Bertrand, T., Beck, T., Wijdenes, J., Brochier, J., & Klein, B. (1995) · Blood · doi:10.1182/blood.v86.2.685.bloodjournal862685 · Cited by 269
Self-citationInterleukin-6 prevents dexamethasone-induced myeloma cell death
Hardin, J., MacLeod, S., Grigorieva, I., Chang, R., Barlogie, B., Xiao, H., & Epstein, J. (1994) · Blood · doi:10.1182/blood.v84.9.3063.3063 · Cited by 262
Gunn, W. G., Conley, A., Deininger, L., Olson, S. D., Prockop, D. J., & Gregory, C. A. (2006) · Stem Cells · doi:10.1634/stemcells.2005-0220 · Cited by 261
RANK ligand and osteoprotegerin in myeloma bone disease.
Sezer, O., Heider, U., Zavrski, I., Kühne, C. A., & Hofbauer, L. C. (2003) · Blood · doi:10.1182/blood-2002-09-2684 · Cited by 258
Allen, M. J., Myer, B. J., Khokher, A. M., Rushton, N., & Cox, T. M. (1997) · QJM · doi:10.1093/qjmed/90.1.19 · Cited by 245
Baran, P., Hansen, S., Waetzig, G. H., Akbarzadeh, M., Lamertz, L., Huber, H. J., Ahmadian, M. R., Moll, J. M., & Scheller, J. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra117.001163 · Cited by 235
Survival and Proliferation Factors of Normal and Malignant Plasma Cells
Klein, B., Tarte, K., Jourdan, M., Mathouk, K., Moreaux, J., Jourdan, E., Legouffe, E., Vos, J. D., & Rossic, J. F. (2003) · International Journal of Hematology · doi:10.1007/bf02983377 · Cited by 215
“(3) Serum levels of IL-6 and soluble IL-6R are increased in patients with MM in association with a poor prognosis [ 18 ,19].”
BackgroundSelf-citationInterleukin-6 and its relation to inflammation and disease
Hirano, T. (1992) · Clinical Immunology and Immunopathology · doi:10.1016/0090-1229(92)90042-m · Cited by 208
Avet-Loiseau, H., Durie, B. G. M., Cavo, M., Attal, M., Gutierrez, N., Haessler, J., Goldschmidt, H., Hajek, R., Lee, J. H., Sezer, O., et al. (2013) · Leukemia · doi:10.1038/leu.2012.282 · Cited by 181
Kiziltepe, T., Hideshima, T., Catley, L., Raje, N., Yasui, H., Shiraishi, N., Okawa, Y., Ikeda, H., Vallet, S., Pozzi, S., et al. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-0010 · Cited by 180
Defective development of pristane-oil-induced plasmacytomas in interleukin-6-deficient BALB/c mice.
(1997) · Europe PMC (PubMed Central) · Cited by 111
IL6R-STAT3-ADAR1 (P150) interplay promotes oncogenicity in multiple myeloma with 1q21 amplification
Teoh, P. J., Chung, T.-H., Chng, P. Y. Z., Toh, S. H. M., & Chng, W. J. (2020) · Haematologica · doi:10.3324/haematol.2019.221176 · Cited by 60
Metadata
- Authors
- Bataille, R., Jourdan, M., Zhang, X. G., & Klein, B.
- Venue
- Journal of Clinical Investigation
- Published
- 1989-12-01
- Volume
- 84
- Issue
- 6
- Pages
- 2008-2011
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W1973965625
- Cited by
- 479
- References
- 13
- FWCI
- 13.39
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.